EdiGene is a biotechnology company using genetic editing technologies to develop therapies for the treatment of cancer and genetic diseases that is headquartered in Tokyo, JapanJapan and was founded in 2015 by Haru Morita and Osamu Nureki. The company is using its proprietary CRISPR and protein engineering platforms with technologies licensed intellectual property from the University of Tokyo.
The programmed chromosome fission technique adapts CRISPR-Cas9 to excise long stretches without leaving unwanted errors of “genetic scars”. After a segment of DNADNA is excised, the programmed chromosome fusion technique uses an altered version of lambda red recombinase to join the ends of both the original chromosome and the excised piece to form two circular DNA molecules that are protected form endonucleases. The smaller DNA segments will be easier to make changes to and they can later be combined back together.